Navigation Links
Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
Date:10/21/2007

Japan, Plavix(R) is the only widely approved antiplatelet agent used in monotherapy for prevention of atherothrombotic events in patients with recent myocardial infarction (hear attack), recent ischaemic stroke or established peripheral arterial disease, and in combination with acetylsalicylic acid for the treatment of patients with acute coronary syndrome (unstable angina or NSTEMI) including those who are to be managed medically and those managed with PCI (with or without stent) and for STEMI patients.

Plavix(R) is one of the most studied cardiovascular medications available to patients with short and long term clinical benefit, and after a decade of prescriptions, it remains the oral antiplatelet therapy with the broadest range of indications worldwide.

About Plavix(R)

Plavix(R), also marketed as Iscover(R), is an antiplatelet agent which prevents platelets from sticking together and forming clots in the arteries. Plavix(R) was first authorized in the United States in 1997 and the European Union in 1998 and has been prescribed to more than 70 millions patients worldwide.

In Japan, in addition to the new approval for acute coronary syndrome (unstable angina pectoris, non-ST elevation myocardial infarction) for which percutaneous coronary intervention (PCI) is planned, Plavix(R) is also approved for "reduction of recurrence after ischemic cerebrovascular disorder (excluding cardiogenic cerebral embolism)" one of the 3 major causes of death in Japan.

The efficacy and safety profile of Plavix(R) have been established through landmark clinical trials including more than 100,000 patients worldwide. Outside Japan, Plavix(R) has shown favourable tolerability profile as compared to ASA and an acceptable increase in major bleedings when used in combination with ASA (no statistical difference when only PCIs are considered).

In Japan, Plavix(R) is marketed by sanofi-aventis K.K. Plavix(R) is marketed in more than 100 countries by sanofi-a
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
2. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
3. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. New Data from the US and Japan Support: No Established Causal Link Between Neuropsychiatric Symptoms and Treatment with Tamiflu US Databases Indicate Psychiatric Symptoms Lower in Influenza Patients Taking Tamiflu Versus Those Not Taking Tamiflu
7. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
(Date:1/22/2015)... 22, 2015  ViewRay™, a privately held medical device company, ... distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: ... the treatment of cancer in Japan ... world,s first and only MRI-guided radiation therapy system that ...
(Date:1/22/2015)... Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty ... disease and overall health is pleased to provide you with ... outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi ... like to take this opportunity to share with you the ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... 31, 2011 AAIPharma Services Corp., a leading ... announced today the promotion of Dean Shirazi, Ph.D., ... the position effective April 4, 2011. ... Shirazi, who joined AAIPharma in June 1992 as ...
... Reportlinker.com announces that a new market research report ... Molecular Diagnostics in Infectious Disease Testing ... This TriMark Publications report describes the specific segment ... molecular diagnostics testing for infectious disease. In the ...
Cached Medicine Technology:AAIPharma Services Announces Promotion of Dean Shirazi 2Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 2Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 3Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 4Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 5Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 6Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 7Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 8Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 9Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 10Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 11Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 12Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 13Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 14Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 15Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 16Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 17Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 18
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the basic ... , Purchasing an accidental death and dismemberment rider for a ... rider provides benefits if the insured dies in an accident. ... of life insurance. , AD&D is not expensive and ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... Weddingshe.com has added many trendy Champagne wedding dresses ... in the past three years. Today, the business announces a ... to the sales manager of the company, this is on ... This point can be reflected on the discounted wedding dresses ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... people with type 1 version of disease , WEDNESDAY, Aug. ... proteins may contribute to type 1 diabetes, Canadian researchers say. ... found that nearly half had immune system T-cells that overreacted ... abnormal immune response. , "The immune system has to find ...
... but actual amount still small , WEDNESDAY, Aug. 26 (HealthDay ... radiation Americans would otherwise be exposed to, new research shows. ... three-quarters of the exposure, and more than 80 percent of ... Fazel, senior author of a study appearing in the Aug. ...
... contribute to drug resistance in non-small cell lung cancer ... access journal BMC Cancer found good correlation ... and resistance and actual in vitro chemosensitivity. Ian ... team of researchers who assessed the chemosensitivity of a ...
... , DES MOINES, Iowa, Aug. 26 Briggs, the ... solutions to long term care facilities, today announced a unique program to ... certified nursing homes. , , Briggs, new ... in response to the five-star rating system implemented late last year by ...
... ... in cooperation with FDA and PhRMA, will host Progression-Free Survival Oncology Workshop from October ... ... Association (DIA), in cooperation with FDA and PhRMA, will host Progression-Free Survival ...
... 26 With this morning,s passing of Massachusetts Senator Ted Kennedy ... it could lead to quicker diagnoses for others affected by the ... In 2005, Grundner established The Kelly Heinz-Grundner Brain Tumor Foundation ... his position as Senior Vice President at JPMorgan Chase to dedicate ...
Cached Medicine News:Health News:Medical Scans a Significant Source of Radiation 2Health News:Medical Scans a Significant Source of Radiation 3Health News:Briggs Program Improves Care in Nation's Nursing Homes 2Health News:Briggs Program Improves Care in Nation's Nursing Homes 3Health News:DIA/FDA/PhRMA to Host Progression-Free Survival Oncology Workshop 2Health News:DIA/FDA/PhRMA to Host Progression-Free Survival Oncology Workshop 3
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
... microplate spectrophotometer designed specifically to run 24 ... With rugged hardware, proven optical performance and ... of traditional spectrophotometry to obtain results quickly, ... read up to eight, 1 cm Biocell ...
... The 1100RS Spectrophotometers ... economical. Great for use ... laboratories, including educational, clinical, ... Options include COD vial ...
Spectra 2000 Digital Spectrophotometer is designed for quantitative and qualitative analysis in visible range from 320 nm to 1020 nm....
Medicine Products: